Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab

@article{Oliveira2011CompleteRI,
  title={Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab},
  author={Mafalda Oliveira and Sofia Braga and Jos{\'e} Lu{\'i}s Passos-Coelho and Ricardo Fonseca and Jo{\~a}o Carlos Nunes de Oliveira},
  journal={Breast Cancer Research and Treatment},
  year={2011},
  volume={127},
  pages={841-844}
}
Trastuzumab, a monoclonal antibody against the HER2 receptor, is a major breakthrough in the treatment of HER2+ breast cancer. However, its high molecular weight precludes it from crossing the intact blood–brain barrier, making the central nervous system a sanctuary to HER2+ breast cancer metastases. We prospectively assessed functional outcome and toxicity… CONTINUE READING